MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection

E Lugli; M Pinti; M Nasi; L Troiano; N Prada; C Mussini; V Borghi; R Esposito; A Cossarizza

doi:10.1111/j.1744-313X.2005.00523.x

MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection

Int J Immunogenet. 2005 Oct;32(5):269-71. doi: 10.1111/j.1744-313X.2005.00523.x.

Authors

E Lugli¹, M Pinti, M Nasi, L Troiano, N Prada, C Mussini, V Borghi, R Esposito, A Cossarizza

Affiliation

¹ Department of Biomedical Sciences, Chair of Immunology, University of Modena and Reggio Emilia, 41100 Modena, Italy.

PMID: 16164692
DOI: 10.1111/j.1744-313X.2005.00523.x

Abstract

Matrix metalloproteinase-7 (MMP-7) generates soluble Fas Ligand (FasL), which is involved in the apoptotic loss of CD4+ T cells during HIV infection. We evaluated whether two polymorphisms in MMP-7 promoter could influence CD4+ recover in response to antiretroviral therapy, and found that these polymorphisms are ineffective.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-Retroviral Agents / therapeutic use
CD4 Lymphocyte Count / methods
CD4-Positive T-Lymphocytes / immunology*
CD4-Positive T-Lymphocytes / virology
HIV Infections / genetics
HIV Infections / immunology*
HIV-1 / immunology*
Humans
Male
Matrix Metalloproteinase 7
Metalloendopeptidases / genetics
Metalloendopeptidases / immunology*
Middle Aged
Polymorphism, Genetic / genetics
Polymorphism, Genetic / immunology*
Viral Load* / methods

Substances

Anti-Retroviral Agents
Metalloendopeptidases
MMP7 protein, human
Matrix Metalloproteinase 7